Related Experiment Video
Updated: Apr 18, 2026

Investigation of the Transcriptional Role of a RUNX1 Intronic Silencer by CRISPR/Cas9 Ribonucleoprotein in Acute Myeloid Leukemia Cells
Published on: September 1, 2019
Runx3 at the interface of immunity, inflammation and cancer
Joseph Lotem1, Ditsa Levanon1, Varda Negreanu1
1Department of Molecular Genetics, Weizmann Institute of Science, Rehovot 76100, Israel.
Abstract:
Inactivation of tumor suppressor genes (TSG) in normal cells provides a viability/growth advantage that contributes cell-autonomously to cancer. More than a decade ago claims arose that the RUNX3 member of the RUNX transcription factor family is a major TSG inactivated in gastric cancer, a postulate extended later to other cancers. However, evidence that Runx3 is not expressed in normal gastric and other epithelia has challenged the RUNX3-TSG paradigm. Here we critically re-appraise this paradigm in light of recent high-throughput, quantitative genome-wide studies on thousands of human samples of various tumors and new investigations of the role of Runx3 in mouse cancer models. Collectively, these studies unequivocally demonstrate that RUNX3 is not a bona fide cell-autonomous TSG. Accordingly, RUNX3 is not recognized as a TSG and is not included among the 2000 cancer genes listed in the "Cancer Gene Census" or "Network for Cancer Genes" repositories. In contrast, RUNX3 does play important functions in immunity and inflammation and may thereby indirectly influence epithelial tumor development.
Insights
RUNX3 is not a tumor suppressor gene (TSG) in epithelial cells, contrary to previous claims. New evidence shows RUNX3 influences immunity and inflammation, indirectly affecting cancer development.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Tumor suppressor genes (TSGs) inactivation confers a growth advantage, promoting cancer.
- RUNX3 was previously hypothesized to be a major TSG inactivated in gastric and other cancers.
Purpose of the Study:
- To critically re-appraise the paradigm of RUNX3 as a cell-autonomous TSG.
- To evaluate the role of RUNX3 in cancer development based on recent high-throughput studies and mouse models.
Main Methods:
- Analysis of high-throughput, quantitative genome-wide studies on thousands of human tumor samples.
- Investigation of the role of Runx3 in mouse cancer models.
Main Results:
- RUNX3 is not expressed in normal gastric and other epithelia, challenging its TSG status.
- RUNX3 is not a bona fide cell-autonomous TSG and is absent from major cancer gene repositories.
- RUNX3 plays significant roles in immunity and inflammation, potentially influencing epithelial tumor development indirectly.
Conclusions:
- The hypothesis of RUNX3 as a direct tumor suppressor gene is refuted by current evidence.
- RUNX3's functions in immunity and inflammation may indirectly impact epithelial tumorigenesis.
Related Concept Videos
Inflammatory Bowel Disease III: Crohn's Disease
Psychoneuroimmunology: Diabetes and Cancer
Mechanisms of Retrovirus-induced Cancers
Mechanisms of Retrovirus-induced Cancers
Inheritance of Chromatin Structures
Abnormal Proliferation
